Skip Navigation

Repertoire Immune Medicines Enters Collaboration to Advance Novel Antigen Discovery and T Cell Receptor Research in Melanoma

  • Collaboration seeks to identify novel antigenic reactivity of T cells in patients with late stage, advanced metastatic melanoma using Repertoire’s DECODE platform

CAMBRIDGE, Mass. – May 26, 2021 – Repertoire Immune Medicines, a clinical-stage biotech company decoding the immune synapse to create novel immune therapies for cancer, immune disorders, infectious disease, and other serious diseases, today announced a new collaboration with a Yale School of Medicine research team focused on identifying antigens expressed in patients with late-stage, advanced metastatic melanoma, and determining which of these antigens activate T cells in the tumor. The collaboration will seek to understand the specificity of various subsets of T cells with the goal of uncovering new antigens and their T cells, with potential for future incorporation into Repertoire’s cell therapy and other development programs.

The study will discover new immunodominant epitopes and determine the specificity of T cells obtained from patients with metastatic melanoma. The university research team will provide human T cell receptor (TCR) sequences to Repertoire, which will use its proprietary DECODE™ platform to determine the novel antigens that these TCRs identify. The team’s deep understanding of translational science in oncology, coupled with Repertoire’s platform technology, may generate unique insights leading to the development of novel immune medicines.

The research team will be led by David A. Hafler, MD, FANA, William S. and Lois Stiles Edgerly Professor of Neurology and Professor of Immunobiology, Yale School of Medicine; Chair, Department of Neurology and Neurologist-in-Chief, Yale New Haven Hospital.

“We’re pleased to initiate this collaboration with Dr. Hafler and his team at Yale University, particularly given their deep expertise in pioneering translational science in difficult disease areas, including advanced melanoma,” said Anthony Coyle, Ph.D., President, Research and Development, Repertoire Immune Medicines. “Our hope is that this collaboration will unveil breakthrough science that we can apply to transformational drug discovery and development of novel immune therapies for melanoma patients in need.”

About Repertoire Immune Medicines

Repertoire Immune Medicines is a fully integrated immune medicines company dedicated to creating treatments for serious diseases based on the power of the human T cell repertoire to eliminate cancer cells, target pathogens and regulate immune function. Repertoire’s strategy lies in understanding the immune synapse – the interaction between specific T cells and the corresponding antigen presenting cells that dictate T cell activity. The company’s proprietary DECODE™ technology platform, developed by Repertoire scientists, provides a unique understanding of the full repertoire of interactions between T cell receptors (TCRs) and their antigen targets. The ability to decode these interactions represents one of the greatest opportunities for innovation in medical science.

Repertoire’s team of more than 120 operates from sites in Cambridge, Massachusetts, and Zurich, Switzerland, using its DECODE technology to rationally design treatments for cancers, autoimmune disorders, and infectious disease. The company’s first product in the clinic, for metastatic solid tumors, is a novel multiclonal T cell therapy consisting of naïve, rare T cells derived from the peripheral blood, activated against a curated set of antigens, and armed with a proprietary cytokine payload. In the field of autoimmunity, Repertoire has discovered novel immune targets from patients with type 1 diabetes and other autoimmune diseases, providing the foundation for novel therapeutic candidates. The company is also using its DECODE platform to discover infectious disease antigens and responding T cell clones, providing the opportunity to develop targeted medicines for infectious diseases. To date, the company has raised more than $350 million from leading healthcare investors.

Investor Contact:

Kendall Investor Relations
Carlo Tanzi, Ph.D.
ctanzi@kendallir.com

Media Contact:

Scient Public Relations
Lindsay G. Deefholts
ldeefholts@scientpr.com